We are a group of privately held biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.



Acquired by Millendo Therapeutics in December 2017



Acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) in March 2016


Program: IGFBP-2 peptides for rare metabolic and musculoskeletal diseases


Status: Preclinical